Insider · CIK 0001891933
Menghisteab Bairu
Files at BCLI (BRAINSTORM CELL THERAPEUTICS INC.). First filing -, latest -.
In brief
Menghisteab Bairu files SEC Form 4 as director at BCLI (BRAINSTORM CELL THERAPEUTICS INC.). No open-market trade is on file; the transactions below are grants, exercises and other rows that carry no view on the price.
A track record needs three past buys with six months of prices behind them; Menghisteab Bairu has 0, so none is measured yet.
Signals
This insider’s open-market buys and sells, scored.
Transactions
Every row this insider has filed, 2 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Feb 26, 2026 | BCLI BRAINSTORM CELL THERAPEUTICS INC. | AGrant or award Stock Option (Right to Buy)derivative | +150,000 | $0.70 | $105k | 150,000 | May 20, 2026 |
| Jan 1, 2025 | BCLI BRAINSTORM CELL THERAPEUTICS INC. | AGrant or award Common Stock | +24,000 | $0.00 | $0 | 24,000 | Jan 3, 2025 |
Questions about Menghisteab Bairu
Answered from the filings on this page, as of the latest one.
Is Menghisteab Bairu buying or selling?
Menghisteab Bairu has no open-market buy or sell on SEC Form 4; the filings on record are grants, exercises and other transactions.
How did Menghisteab Bairu's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Menghisteab Bairu has 0.
Where does Menghisteab Bairu file Form 4?
Menghisteab Bairu has filed Form 4 at BCLI (BRAINSTORM CELL THERAPEUTICS INC.). A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.